
ExpressionEdits Founded by Dr Kärt Tomberg and Professor Allan Bradley, the company has developed the world’s first AI-driven Genetic Syntax Engine, trained on billions of data points from years of proprietary experiments. Today’s synthetic transgenes lack the intron–exon architecture characteristic of natural genes, a fundamental mismatch that limits RNA processing, export, and stability. ExpressionEdits’ intronized designs recreate this natural structure, yielding superior RNA quality and higher protein expression across biologics and gene therapies. The company has built the largest and highest-quality dataset in the field, validated its platform through licensing deals, including a multi-asset partnership with Boehringer Ingelheim in gene therapy, and is advancing an internal pipeline of recombinant protein therapeutics, with a lead program in hematology. ExpressionEdits has raised $13M from Octopus Ventures, Redalpine, BlueYard, Wilbe, AceCap, Amino, and Hawktail, to advance a new class of intron-enabled genetic medicines. Therapeutic Developer

ExpressionEdits

Founded by Dr Kärt Tomberg and Professor Allan Bradley, the company has developed the world’s first AI-driven Genetic Syntax Engine, trained on billions of data points from years of proprietary experiments. Today’s synthetic transgenes lack the intron–exon architecture characteristic of natural genes, a fundamental mismatch that limits RNA processing, export, and stability. ExpressionEdits’ intronized designs recreate this natural structure, yielding superior RNA quality and higher protein expression across biologics and gene therapies. The company has built the largest and highest-quality dataset in the field, validated its platform through licensing deals, including a multi-asset partnership with Boehringer Ingelheim in gene therapy, and is advancing an internal pipeline of recombinant protein therapeutics, with a lead program in hematology. ExpressionEdits has raised $13M from Octopus Ventures, Redalpine, BlueYard, Wilbe, AceCap, Amino, and Hawktail, to advance a new class of intron-enabled genetic medicines.

Therapeutic Developer